Related Experiment Video
Updated: Jun 5, 2026

07:20
Discovery and Synthesis Optimization of Isoreticular Al(III) Phosphonate-Based Metal-Organic Framework Compounds Using High-Throughput Methods
Published on: October 6, 2023
Solid-State Forms of β-Resorcylic Acid: How Exhaustive Should a Polymorph Screen Be?
Crystal Growth & Design
|January 11, 2011
Summary
Researchers discovered seven new solid-state forms of beta-resorcylic acid through experiments and computational analysis. A reversible transformation was observed between the stable form and a new high-temperature form.
Area of Science:
- Solid-state chemistry
- Crystallography
- Materials science
Background:
- Beta-resorcylic acid is a compound with potential applications.
- Understanding its solid-state forms is crucial for its use.
- Polymorphism influences material properties.
Purpose of the Study:
- To identify and characterize new solid-state forms of beta-resorcylic acid.
- To investigate phase transformations between different forms.
- To provide a comprehensive understanding of beta-resorcylic acid's solid-state behavior.
Main Methods:
- Extensive experimental screening (e.g., crystallization techniques).
- Computational studies (e.g., theoretical modeling).
- Solid-state characterization techniques (e.g., X-ray diffraction, thermal analysis).
Main Results:
- Seven novel solid-state forms of beta-resorcylic acid were identified.
- A reversible phase transformation was observed between the known stable polymorph II° and a new high-temperature form (form I).
- The new high-temperature form is likely kinetically stable and disordered.
Conclusions:
- The study elucidates the complex solid-state landscape of beta-resorcylic acid.
- New forms and a reversible phase transition were characterized.
- This work offers a consistent understanding of beta-resorcylic acid's solid-state properties.
Related Concept Videos
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

